Cargando…
Anti-tumor efficacy of an MMAE-conjugated antibody targeting cell surface TACE/ADAM17-cleaved Amphiregulin in breast cancer
BACKGROUND: The Epidermal Growth Factor Receptor (EGFR) ligand, Amphiregulin (AREG), is a key proliferative effector of estrogen receptor signaling in breast cancer and also plays a role in other malignancies. AREG is a single-pass transmembrane protein proteolytically processed by TACE/ADAM17 to re...
Autores principales: | Lofgren, Kristopher A, Sreekumar, Sreeja, Jenkins Jr, E Charles, Ernzen, Kyle J, Kenny, Paraic A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643873/ https://www.ncbi.nlm.nih.gov/pubmed/34877472 http://dx.doi.org/10.1093/abt/tbab026 |
Ejemplares similares
-
Pan-cancer distribution of cleaved cell-surface amphiregulin, the target of the GMF-1A3 antibody drug conjugate
por: Lofgren, Kristopher A, et al.
Publicado: (2022) -
ADAM17 is essential for ectodomain shedding of the EGF‐receptor ligand amphiregulin
por: Hosur, Vishnu, et al.
Publicado: (2018) -
Bivalent EGFR-Targeting DARPin-MMAE Conjugates
por: Karsten, Lennard, et al.
Publicado: (2022) -
Guanidine-modified albumin-MMAE conjugates with enhanced endocytosis ability
por: Yi, Ce, et al.
Publicado: (2023) -
ADAM17/TACE: a key molecule in brain injury regeneration
por: Domínguez-García, Samuel, et al.
Publicado: (2019)